Hesperidin enhanced anti-breast cancer effect and alleviated cisplatin induced nephrotoxicity through silk fibroin delivery system
- Toxicol Appl Pharmacol. 2025 Feb:495:117234. doi: 10.1016/j.taap.2025.117234.
- 1. Department of Radiotherapy, The Affiliated Hospital of Qingdao University, Qingdao 266000, China; School of Public Health, Qingdao University, Qingdao 266071, China.
- 2. Department of Radiotherapy, The Affiliated Hospital of Qingdao University, Qingdao 266000, China.
- 3. Department of Radiotherapy, Yizhou Tumor Hospital, Zhuozhou 072750, China; Department of Radiotherapy, University of Tsukuba Hospital, Tsukuba, Japan.
- 4. Department of Radiotherapy, University of Tsukuba Hospital, Tsukuba, Japan.
- 5. Graduate School of Environmental Science, Hokkaido University, Sapporo, Hokkaido, Japan.
- 6. Hauolilly-MEDICAL company, Tokyo, Japan.
- 7. Qingdao University of Science and Technology, Qingdao 266041, China.
- 8. Department of Radiotherapy, The Affiliated Hospital of Qingdao University, Qingdao 266000, China. Electronic address: [email protected].
The incidence rate and mortality rate of breast Cancer remain high, and there is an urgent need for safe and effective drugs. The excellent biological activity of hesperidin (HE) is a potential drug for the treatment of breast Cancer. In this study, silk fibroin peptides (SFP) were used as delivery carriers and HE loaded SFP nanofibers (SFP/HE NFs) was prepared. The in vitro results showed that SFP/HE NFs significantly inhibited the proliferation and migration of breast Cancer cell MDA-MB-231 compared with free HE. The mechanism results demonstrated that SFP/HE NFs induced Apoptosis and DNA double stranded damage (DSBs) and further activated the cyclic monophosphate guanosine adenosine monophosphate synthase- stimulator of interferon gene (cGAS-STING) pathway. The in vivo studies showed that SFP/HE NFs treatment significantly inhibited the growth of breast Cancer, with an inhibition rate of 65.9 % (100 mg/kg). In vivo mechanism studies also demonstrated that the anti-tumor activity of SFP/HE NFs was related to the activation of the cGAS-STING pathway. Interestingly, we found that the combination of SFP/HE NFs and cisplatin not only enhanced the anti-tumor activity of cisplatin, but also alleviated cisplatin induced nephrotoxicity. In conclusion, our results demonstrate the benefits of activating the cGAS-STING pathway in the treatment of breast Cancer, which is expected to provide potential candidates for combined treatment of breast Cancer.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Cyclic GMP-AMP SynthaseResearch Areas: Metabolic Disease